AstraZeneca at plenary again with pivotal ASCO data

UK pharma major AstraZeneca (LSE: AZN) is set to present data from more than 80 studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Spanning across 20 approved and investigational medicines, the presentations include two plenary sessions and a special late-breaking abstract.

Among the headlining presentations is the Phase III SERENA-6 trial evaluating camizestrant, an investigational selective estrogen receptor degrader, in combination with CDK4/6 inhibitors. This marks the first late-stage study to demonstrate positive results for a next-generation oral SERD in the first-line setting for patients with hormone receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations.

The DESTINY-Breast09 trial will also feature at the meeting, offering updated findings on the use of Enhertu (fam-trastuzumab deruxtecan-nxki), developed in partnership with Japan’s Daiichi Sankyo (TSE: 4568), in combination with Perjeta (pertuzumab). This regimen is being assessed against the current first-line standard for HER2-positive metastatic breast cancer.